Patient Age/Gender: 28 years Female Printed: 31-Aug-18 13:04:54

					Reported/
Procedure	Result	Units	Ref Interval	Accession Collected Received	Verified
Carbamazepine 10-11 Epoxide	4.6	ug/mL	-	18-243-900118 31-Aug-18 31-Aug-1	8 31-Aug-18
				13:02:00 13:02:00	13:04:20
Carbamazepine, Total	12.5 H	ug/mL	[4.0-12.0]	18-243-900118 31-Aug-18 31-Aug-1	8 31-Aug-18
				13:02:00 13:02:00	13:04:20

31-Aug-18 13:02:00 Carbamazepine 10-11 Epoxide: INTERPRETIVE INFORMATION: Carbamazepine-10, 11-Epoxide

Carbamazepine-10, 11 Epoxide Therapeutic Range: Not well established

Toxic: Greater than 15.0 ug/mL

Total Carbamazepine Therapeutic Range: 4.0-12.0 ug/mL

Toxic: Greater than 15.0 ug/mL

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. The carbamazepine metabolite, Carbamazepine-10, 11-Epoxide, has anticonvulsant activity and a proposed therapeutic range of $0.4-4 \mu g/mL$.

A rare, adverse drug reaction to carbamazepine therapy includes Stevens-Johnson syndrome or toxic epidermal necrolysis. Patients of Asian ancestry with the presence of the HLA-B*15:02 have an increased risk for this carbamazepine-induced, life-threatening reaction. Pharmacogenetic testing for HLA-B*15:02 is recommended prior to treatment for patients at risk of carbamazepine hypersensitivity. This information has been included in the FDAapproved label for carbamazepine (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varAppl No=016608) and in the guideline from the Clinical Pharmacogenetics Implementation Consortium (https://www.pharmgkb.org/guidelines). [HLA-B*15:02 Genotyping, Carbamazepine Hypersensitivity, ARUP test code 2012049.]

A combination of therapeutic drug monitoring with HLA-B*15:02 pharmacogenetics genotyping may benefit patients at increased risk of developing carbamazepine-induced adverse events due to rare genotypes other than the HLA-B*15:02 variant allele.

See Compliance Statement B: www.aruplab.com/CS